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Introduction
Harms of drugs are an important cause of mortality and morbidity. The use of pharmaceuticals
always entails a risk of adverse events, often to an unknown extent, and increased drug utilization
has made drug-related problems a common occurrence (1). It is, for instance, estimated that adverse
drug reactions (ADRs) cause the European Union almost 200,000 deaths annually (2) and cost
approximately AC79 billion (3).
The World Health Organization (WHO) clearly recognizes the need for prescribed medicines to
be of good quality, safe, effective, and used by the right patient in the right dose at the right time
in order to minimize the risk of harm (4). The thalidomide disaster around 1960 underscored the
necessity of systems to monitor medicines safety after marketing. As a consequence, governments
developed systems in order to affirm that drug products are safe and efficacious enough to be
permitted on the market and that the pharmaceutical industry needed to be regulated since these
companies have a responsibility to protect public health (5). This concern with patient safety and
the rational usage of drugs is often referred to as pharmacovigilance (PV) (6), which can be defined
as “the science and activities relating to the detection, assessment, understanding, and prevention
of adverse events or any other possible drug-related problems” (7). It is however well established
that knowledge about medicines safety is limited at the time of licensing of a new product and
spontaneous reporting of ADRs to regulatory authorities and drugmanufactures is perhaps themost
important way of monitoring the post-market safety of medicines (8). National databases to collect
signals of ADRs from health care professionals (HCPs) were established already from the late 1960s
and aWHO international collaboration started in 1968.With theirDrugMonitoring Program, WHO
supports the reporting of potential ADRs by HCPs (9), but it is a well-recognized problem by the
Organization, that this group under-report serious and fatal reactions (4). Unexpected ADRs are,
for instance, seldom reported.
Consumer Reporting
To allow the general public to report directly to the authorities, so-called consumer reporting, has
been presented as an alternative way to increase ADR reporting. This is sometimes also referred to
as direct patient reporting (DPR). An advantage in using the term “consumer reporting” is that it
clarifies that it is referring to direct reporting from the person affected (instead of reporting within
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or via a health care setting) and that it is a matter of consumer
rights. The term is also used by the WHO (10).
Some concernswith this kind of direct reporting have, however,
been raised. First, there is the potential lack of medical confirma-
tion that may hamper the analysis of cause and effect between
the drug and the adverse event (11). Second, there have been
some concerns that media potentially might influence consumer
reports and thereby provide more selected reporting than from
health professionals and as a consequence complicate analysis.
Third, critics (mostly health professionals and regulatory agen-
cies) previously stated that consumer reports would create “noise”
and prove a drain on surveillance systems (7, 12). Despite these
concerns, several research studies in the last decade or so have
suggested that consumer reports instead can add value to HCP
reports by identifying potential new adverse reactions (13–17)
and considerably contribute to reliable PV systems (18). On the
contrary to critical beliefs, subjective toxicities are instead at high
risk of being under-reported by physicians, and the WHO states
that consumer reporting can be an important aspect to both
help the individual patient to receive optimal therapy and also to
safeguard public health programs (7).
Today, around 46 countries have some kind of national
consumer reporting system (18). Citizens in the US, Canada,
Australia, and New Zealand have had the possibility to report
ADRs directly since the 1960s, while in other countries, including
Denmark, the Netherlands, the UK, and Sweden, reporting has
only been available since 2003 and later. Since 2012, all EU
countries are obliged to establish patient/consumer reporting
within their spontaneous reporting systems as a part of the new
European pharmacovigilance legislation (Directive 2010/84/EU)
(Regulation 1235/2010) (19). The purpose of this legislation is to
improve patient safety and public health and to further accentuate
patient influence. This approach clearly indicates a change in
attitude in which patients’ experiences are valued and believed
to accelerate the acquisition of knowledge about ADRs. Still,
the awareness that patients and consumers can report ADRs is
thought to be low in most countries and there is a low awareness
of available reporting systems (20). It has also been argued that
many consumer reporting systems focus only on adverse events,
missing out on other aspects of medicine use, such as experiences
in ineffectiveness (13).
Consumer Reporting in Sweden
In Sweden, it has only been possible for the general public to sub-
mit reports to the Medical Products Agency (MPA, the national
medicines regulatory authority) since 2008. Consumers have the
option to report electronically direct on the MPA website or
by printing out the report scheme and send it via regular mail.
The agency now regards these consumer reports to be a valuable
contribution in the monitoring of safety aspects in medicines (16)
despite previous concerns like the above mentioned.
Before the MPA implemented consumer reporting in Swe-
den, the public had since 1997 had the possibility to report
ADRs to the consumer organization KILEN (Consumer Institute
for Medicines and Health), working on consumer rights issues
of dependence, side effects, and injuries related to medicines.
This organization established a consumer database in 1997 to
collect consumer reports, mainly focusing on benzodiazepines
and antidepressants. Reports came mainly through personal con-
tact by telephone and visits. This gave the possibility for con-
sumers to report suspected ADRs and to share their experience of
medicine use. In 2002, KILEN also introduced the possibility for
the public to report suspected ADRs via an online report form on
their webpage allowing for the reporting consumer to add free text
comments of their ADR experiences. Reported drugs to KILEN
were coded according to the Anatomical Therapeutic Chemical
(ATC) classification and reported ADRs according to MedDRA®
terminology.
KILEN as a consumer institute was unexpectedly forced to
cease operations in March 2007, when the Swedish Parliament
(Riksdag) decided not to allow further government grants. It was
however still possible to report ADRs through theweb-based form
to KILEN, but after a couple years as a member organization
KILEN had to shut down their website in 2013.
An Analysis of KILEN Consumer Reports
Unfortunately, the majority of the consumer reports made to
KILEN have not yet been scientifically scrutinized. The exception
is the ones made to the website and an analysis of all submit-
ted reports between the years 2002 and 2009 have shown and
confirmed the importance of consumer reports as an important
complement to HCP reports (21). These ADR reports have been
analyzed both quantitatively (22) and qualitatively, both regarding
the ADR experiences per se (23), but also regarding experiences of
the medical encounter (24). A majority of these reports (70.5%)
concerned antidepressants [mostly selective serotonin-reuptake
inhibitors (SSRIs)]. Other research studies on spontaneous report-
ing systems have shown that ADRs from antidepressants are
commonly reported (13, 25).
Apart from giving a vivid description of users’ symptoms and
suspected adverse reactions, the KILEN reports also indicated
how these experiences affected their daily lives (21). Many of
the consumer reports contained descriptions of experiences of
severe psychiatric adverse effects with antidepressant treatment.
This was especially apparent during discontinuation. This is not
exclusive for the KILEN reports, but has been found in other
reporting systems aswell, for instance theUKYellowCard Scheme
where patients were more likely than HCPs to include informa-
tion about symptoms and the impact it had on them (15). The
UK system also identified new “serious” reactions not already
included in the summary of product characteristics (SPCs), which
was quite apparent in the KILEN consumer reports as well
(22). Experiencing a “sensation of unreality” was, for instance,
a common psychiatric ADR reported to KILEN and not listed
at all as an ADR in the SPC and numerous KILEN narratives
indicated patients experiencing feeling like a “zombie” incapable
of having or sharing feelings toward others, including family
members.
The Problem of Discontinuation
The KILEN consumer reports contained other important findings
as well. Almost one-third of all the psychiatric ADRs reported
happened during discontinuation treatment (mean 30.6%). These
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symptoms were often described as being particularly severe and
problematic. This result is quite congruent with other research,
where abrupt cessation of SSRIs is argued to produce withdrawal
symptoms in up to one-third of the patients (26). Interestingly,
discontinuation symptoms from the KILEN reports were not
always mentioned in the Swedish SPC or regarded as rare. This
is an important finding since discontinuing symptoms can be
regarded by the treating physician as a relapse of the original
disorder (27), which in turn can lead to continued drug treatment
or an increase in dosage. Hence, we encounter a problem of
interpretation; the reported ADR may one the hand occur as a
symptom of the illness for which the antidepressant had been
prescribed in the first place, or it may be a signal of a potential
severe ADR. These kinds of problems were quite apparent in the
KILEN narratives that included reports of consumers perceiving
being dismissed by their doctor regarding the authenticity of
their experienced discontinuation symptoms. Similar dismissive
attitudes amongHCPs have been reported in theUK’s YellowCard
Scheme as well (28).
Anecdotal and Non-Scientific Reports?
As previously mentioned, there is the question of validity of con-
sumer reports. In the past, these reports were mostly dismissed
as anecdotal or non-scientific (29), but research and experience
have shown that patients and consumers can in fact distinguish
between suspected ADRs and other symptoms (30). Consumers
have also been shown to be not only capable of describing their
experiences but also balance the benefits and burden of treatment
(13). What the KILEN narratives adds is that they clearly indicate
that consumer experiences may provide important insight and
ought not to be so easily rejected, but that it also reveals how
patients communicate with their doctors, and how patients often
feel that doctors will not listen. Physicians with good communica-
tion skills will probably not only be able to detect potential ADR
problems earlier but also stimulate ADR reporting and gathering
of information. By preventing medical crises and expensive inter-
ventions, the treating physician can thereby provide better support
to their patient (31).
Consumer Reporting and Public Health
Consumer reports are not only important for the individual but
also can have great significance for public health as well. By
collecting as many experiences as possible, new suspected ADRs
can be detected, meaning that it would be easier to analyze
potential causation on population basis and thereby preventing
unnecessary suffering. Public health is built on trust and harms
to even just a few patients can destroy the credibility and success
of an important public health program (32). As previously argued
by others, combining all reports regardless of reporter type is
recommended since it yields the largest critical mass of reports
for signal detection (16). Further, recognition of these consumer
reported ADRs could prevent misdiagnosis and the worsening of
potentially severe iatrogenic disorders.
When reports contain insufficient details, then doctors and
patients have a false sense of security about the safety of the prod-
uct that they are prescribing and using. Here, consumer reports
can be of special importance since they describe the burden of
ADRs for individuals, which is a major health component that
is missing from public health estimates of disease burden in
populations (33).
The Importance for Future Analysis and
Promotion
The Swedish MPA consumer reporting system developed slowly
with ~400 reports from the public in 2008 to 1,360 in 2014,
with the expectation of a major uneven distribution due to the
vaccination campaign during the A(H1N1) pandemic in 2009,
resulting in 2,541 reports that year. In total, the agency has
received over 7,500 reports from the general public, containing
not only a description of the symptom of a suspected ADR but
also the user’s description in free text. However, these regarding
ports have not been adequately compiled over time or qualita-
tively analyzed, missing out on the consumer experience given
in free text. This is most unfortunate since the KILEN reports
has shown that consumer reports may contribute with significant
information since these reports also include how the medicine is
affecting the user in his or her daily life (21). The MPA reports
ought therefore to be compiled and analyzed in the same way as,
for instance, the Danish and UK national PV systems have been
scrutinized (14, 15).
Unfortunately, the MPA has not promoted and informed the
general public about the possibility to report suspected ADRs
directly to the national agency much. Hence, it is imperative that
consumer reporting is actively promoted to the general public as
soon as possible. Not only via, for instance, the official websites
of drug regulatory agencies and drug product information leaflet
(PIL) but also through public information. As indicated by the
WHO, consumer reporting should be as easy and cheap as pos-
sible with, for instance, easy access to prepaid reporting forms
(10). We know that consumer reporting increases the number of
ADRs reported to PV centers and contributes to signal detection
(16), and consumers aware of ADR self-reporting systems appear
prepared to use them, but promotion of and education on how to
use them are required (20). This could mean for instance active
promotion and raising awareness at local pharmacies through
brochures and information when a medicine [both prescrip-
tion and over-the-counter (OTC)] is purchased. These brochures
could also include easy accessible information of already collected
and analyzed consumer reports. In our digital age, the use of
available social media data for ADR monitoring is being increas-
ingly discussed by researchers (34). The use of social media and
especially Facebook has been suggested as one way to increase
spontaneous ADR reporting (35). There are even specific apps,
for instance MedWatcher, available for reporting side effects of
drugs, vaccines, and medical devices (36). These are all positive
developments since there is also a need for more consumers to
report their experienced suspected ADRs.
In conclusion, if drug regulatory agencies truly want the general
public to report and share their ADR experiences through their
reporting systems, they must (1) inform and promote and inform
the public about their possibility to report suspected ADRs, and
(2) adequately analyze all consumer reports, including the free
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text, in order to monitor the drugs used and to detect and confirm
new ADRs as soon as possible. The public need some kind of
feedback that their experiences are being taken seriously and that
their effort is not being taken for granted. Otherwise, authorities
cannot expect or rely on their citizens to contribute to these kinds
of systems. Thereby, we risk missing out on an important aspect
of public health, that is, monitoring the post-market safety of
medicines.
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